Comparative Pharmacology
Head-to-head clinical analysis: JASCAYD versus PONLIMSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JASCAYD versus PONLIMSI.
JASCAYD vs PONLIMSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JASCAYD (tasquinimod) is a selective allosteric inhibitor of S100A9, which binds to toll-like receptor 4 (TLR4) and receptor for advanced glycation end-products (RAGE). It modulates the tumor microenvironment by inhibiting myeloid-derived suppressor cell (MDSC) recruitment and function, reducing angiogenesis, and enhancing anti-tumor immune responses.
Ponlimsi is a small molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to acetyl-lysine recognition motifs, displacing BET proteins from chromatin, thereby inhibiting transcription of oncogenes such as MYC and BCL2.
Adults: 300 mg orally twice daily with food.
100 mg IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically relevant for once-daily dosing.
Terminal half-life is 24 hours (range 20-28 h), supporting once-daily dosing.
Primarily renal excretion (80%) as unchanged drug; 20% fecal via biliary elimination.
Primarily renal (60% unchanged) and biliary (30% as metabolites), with 10% fecal.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor